CN1115979A - 维生素d类似物的新晶形 - Google Patents

维生素d类似物的新晶形 Download PDF

Info

Publication number
CN1115979A
CN1115979A CN94190868A CN94190817A CN1115979A CN 1115979 A CN1115979 A CN 1115979A CN 94190868 A CN94190868 A CN 94190868A CN 94190817 A CN94190817 A CN 94190817A CN 1115979 A CN1115979 A CN 1115979A
Authority
CN
China
Prior art keywords
calcipotriol
hydrate
crystalline form
vitamin
analogue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN94190868A
Other languages
English (en)
Other versions
CN1040746C (zh
Inventor
E·T·汉森
N·S·拉特楚·安德森
L·H·灵博格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leo Pharma AS
Original Assignee
Leo Pharmaceutical Products Ltd AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10728784&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1115979(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Leo Pharmaceutical Products Ltd AS filed Critical Leo Pharmaceutical Products Ltd AS
Publication of CN1115979A publication Critical patent/CN1115979A/zh
Application granted granted Critical
Publication of CN1040746C publication Critical patent/CN1040746C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C401/00—Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J19/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J19/02—Apparatus characterised by being constructed of material selected for its chemically-resistant properties
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C5/00—Preparation of hydrocarbons from hydrocarbons containing the same number of carbon atoms
    • C07C5/32—Preparation of hydrocarbons from hydrocarbons containing the same number of carbon atoms by dehydrogenation with formation of free hydrogen
    • C07C5/321—Catalytic processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C5/00—Preparation of hydrocarbons from hydrocarbons containing the same number of carbon atoms
    • C07C5/32—Preparation of hydrocarbons from hydrocarbons containing the same number of carbon atoms by dehydrogenation with formation of free hydrogen
    • C07C5/327—Formation of non-aromatic carbon-to-carbon double bonds only
    • C07C5/333—Catalytic processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C5/00—Preparation of hydrocarbons from hydrocarbons containing the same number of carbon atoms
    • C07C5/32—Preparation of hydrocarbons from hydrocarbons containing the same number of carbon atoms by dehydrogenation with formation of free hydrogen
    • C07C5/327—Formation of non-aromatic carbon-to-carbon double bonds only
    • C07C5/333—Catalytic processes
    • C07C5/3335—Catalytic processes with metals
    • C07C5/3337—Catalytic processes with metals of the platinum group
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/02—Apparatus characterised by their chemically-resistant properties
    • B01J2219/0204—Apparatus characterised by their chemically-resistant properties comprising coatings on the surfaces in direct contact with the reactive components
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/02—Apparatus characterised by their chemically-resistant properties
    • B01J2219/0204—Apparatus characterised by their chemically-resistant properties comprising coatings on the surfaces in direct contact with the reactive components
    • B01J2219/0236—Metal based
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/02—Apparatus characterised by their chemically-resistant properties
    • B01J2219/025—Apparatus characterised by their chemically-resistant properties characterised by the construction materials of the reactor vessel proper
    • B01J2219/0277—Metal based
    • B01J2219/0286—Steel
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2523/00—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group C07C2521/00
    • C07C2523/38—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group C07C2521/00 of noble metals
    • C07C2523/40—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group C07C2521/00 of noble metals of the platinum group metals
    • C07C2523/42—Platinum

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

本发明涉及Calcipotriol水合物，一种Calcipotriol的新晶形，具有优越的技术性能和高稳定性。

Description

维生素D类似物的新晶形
本发明涉及一种在结晶悬液制剂的生产中有优越技术特征并具有优越的稳定性能的Calcipotriol水合物—一种Calcipotriol的新晶形。
国际申请NO.PCT/DK86/00081，申请日为1986年7月14日，公开号为WO87/00834，描述了Calcipotriol(INN)(Calcipotriene(US-AN)，(1α，3β，5Z、7E、22E、24S)—24—环丙基—9，10—开环胆甾—5，7—10(19)，22—四烯—1，3，24—三醇)。
Calcipotriol具有优异的生物活性形象，已证明如在局部治疗牛皮癣中非常有用。
由于Calcipotriol在某些溶液中稳定性差，其在某些剂型，特别是霜剂和凝胶中，优选使用结晶悬液。
为了制备适当的结晶悬液制剂，必须能够控制结晶大小，该参数对于得到化合物从制剂中可重复地释放是很重要的。结晶的整体药物在制成最终悬浮液制剂前，一般进行微粒化或进行湿碾磨加工，以减小结晶大小。
对于Calcipotriol，已使用了湿球碾磨加工。当用WO87/00834中描述的无水晶形进行此加工时，已证明在技术上是困难的。这些结晶不易湿润，在碾磨过程中，它们产生稳定的泡沫，这给得到适当的小而均一的颗粒大小带来了困难。
现令人惊异地发现，当使用在此以前未知的Calcipotriol晶形，即Calcipotriol水合物，代替已知的无水晶形时，可以避免这些技术困难。此水合物在技术上优于无水物；它易于湿润，可顺利地进行湿球碾磨加工。
该新产品是Calcipotriol的单水合物，结晶完美、稳定，特别适用于现代治疗中。
稳定性研究表明Calcipotriol水合物令人惊异地稳定，这由40℃的稳定性数据证明。
在此温度下，无水形式的Calcipotriol显示相当程度的分解，在贮存12个月后，发现30％以上的分解。
相反，本发明的化合物—Calcipotriol水合物—在40℃贮存12个月后没有显示分解。
Calcipotriol单水合物可通过将结晶或非结晶Calcipotriol溶解在有机溶剂如乙酸乙酯或丙酮中，然后加入水和任选地加入非极性溶剂如己烷来制备。
Calcipotriol单水合物应形成局部使用的部分药物制剂，如霜剂、软膏、溶液、洗液或凝胶。活性成分的浓度一般将为1—100μg/g。
这些制剂每天可施用一次或多次。
根据本发明制得的制剂包括活性化合物以及药学上可接受的载体和任选的其它治疗成分。载体必须是“可接受的”，意即与制剂的其它成分相容，而不使其接受性变差。
适于局部施用的制剂包括液体或半液体制剂，如搽剂、洗剂、敷剂，水包油或油包水乳剂如霜剂、软膏、糊剂或凝胶；或溶液或悬液。
除了上述提到的成分以外，本发明的制剂还包括一种或多种添加成分，如稀释剂、缓冲液、表面活性剂、增稠剂、润滑剂、防腐剂如羟基苯甲酸甲酯(包括抗氧化剂)、乳化剂等。
在下列非限定性实施例中将进一步说明本发明。
实施例1
将Calcipotriol(2.5g)溶解在50—80℃的乙酸乙酯中，过滤。该溶液用水饱和，自发冷却至室温后，沉淀出了产物。将形成的浆液冷却至0—10℃，过滤。将滤出的产物真空干燥，得到Calcipotriol水合物(2.35g)。
lR光谱(KBr)
该水合物的特征峰分别为1455(m)、1442(m)、1330(W)、1290(m)、1210(m)、1085(m)、907(m)、895(m)和573(W)cm-1。
固态CPMAS(Cross Polarization angle Mugle Spinning)NMR
Calcipotriol水合物的特征共振如下：147.9，146.5，134.8，130.3，129.0，126.5，116.0，109.4，75.5，68.2，67.2，56.9，55.2，47.8，47.5，42.9，42.0，41.3，30.7，28.9，25.6，23.1，22.6，19.5，14.6，6.2和1.9ppm。
示差扫描量热法(DSC)
Perkin Elmer DSC7仪，20℃/分，约2mg样品，该水合物在近117℃失水，在近169.7℃显示熔化峰。
实施例2
将Calcipotriol(22.7g)溶解在甲醇(200—250ml)中，过滤并真空浓缩，将残余物于50—80℃溶解在乙酸乙酯中(200—250ml)，加入水(2ml)。向形成的溶液中加入Calcipotriol水合物晶种，自动冷却至室温，产物沉淀。从滴液漏斗加入己烷(100ml)，冷却形成的浆液至0—10℃，过滤。
滤出的产物用乙酸乙酯和己烷的1∶1混合物(200ml)洗涤，真空干燥，得到Calcipotriol水合物(19.7g)，表明与实施例1中所述产物相同。
实施例3
将Calcipotriol(120mg)溶解在丙酮(2ml)中，加入水(1.5—3ml)。产物自动结晶，将形成的浆液冷却至0—10℃，过滤，将滤出的产物真空干燥，得到Calcipotriol水合物(100mg)，表明其与实施例1中所述产物相同。
实施例4
霜剂50μg/g
Calcipotriol水合物                         50mg
Cetomacrogol 1000                           30g
Cetostearylalcohol                          60g
氯代烯丙基六铵氯化物                       0.5g
丙二醇                                      30g
磷酸氢二钠                                   2g
液体石蜡                                    50g
白软石蜡                                   170g
纯水                                  加至1000g
在75℃将Cetomacrogol 1000。Cetostearylalcohol、液体石蜡和白软石蜡熔化。将丙二醇溶解在75℃水中，将此溶液与脂肪相混合。将此乳液均质化，并冷却至30℃。将Calcipotriol水合物在部分水相中碾磨，使颗粒大小大部分小于10μm，并悬浮在磷酸氢二钠和氯代烯丙基六铵氯化物的水溶液中。将此悬液加到乳液中，将此霜剂填充在管中。实施例5凝胶50μg/g
Calcipotriol水合物                          52.2mg
(相当于50mg无水物)
Carbomer                                        7g
Cetomacrogol 1000                               1g
二氮戊环基脲                                    2g
二氯苄醇                                        1g
乙二胺四乙酸二钠盐                            0.5g
氢氧化钠                                      3.7g
丙二醇                                         30g
纯水                                     加至1000g
将Cetomacrogol、二氮戊环基脲、二氯苄醇、乙二胺四乙酸二钠盐和丙二醇溶解在水中。加入Carbomer，高速均化。搅拌下加入溶解在部分水中的氢氧化钠。在一瓶水中用玻璃珠碾磨Calcipotriol水合物，直到得到小于10μm大小的颗粒。将此Calcipotriol水合物悬液加到凝胶中，混合30分钟。将此凝胶装入可折迭管中。

Claims (5)

1.Calcipotriol，(1α，3β，5Z，7E，22E，24S)—24—环丙基—9，10—开环胆甾—5，7，10(19)，22—四烯—1，3，24—三醇，单水合物。
2.含有权利要求1的化合物的药物组合物。
3.权利要求2的药物组合物，其为霜剂。
4.权利要求2的药物组合物，其为凝胶。
5.权利要求2—4中任一项的药物组合物，其中活性成分的含量为1—100μg/g组合物。
CN94190817A 1993-01-15 1994-01-07 维生素d类似物的新晶形 Expired - Lifetime CN1040746C (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB939300763A GB9300763D0 (en) 1993-01-15 1993-01-15 Chemical compound
GB9300763.1 1993-01-15
PCT/DK1994/000011 WO1994015912A1 (en) 1993-01-15 1994-01-07 New crystalline form of a vitamin d analogue

Publications (2)

Publication Number Publication Date
CN1115979A true CN1115979A (zh) 1996-01-31
CN1040746C CN1040746C (zh) 1998-11-18

Family

ID=10728784

Family Applications (1)

Application Number Title Priority Date Filing Date
CN94190817A Expired - Lifetime CN1040746C (zh) 1993-01-15 1994-01-07 维生素d类似物的新晶形

Country Status (17)

Country Link
US (2) USRE39706E1 (zh)
EP (1) EP0679154B1 (zh)
JP (1) JP3729847B2 (zh)
KR (1) KR100309751B1 (zh)
CN (1) CN1040746C (zh)
AT (1) ATE159717T1 (zh)
AU (1) AU663249B2 (zh)
CA (1) CA2151730C (zh)
DE (1) DE69406529T2 (zh)
DK (1) DK0679154T3 (zh)
ES (1) ES2111287T3 (zh)
FI (1) FI108638B (zh)
GB (1) GB9300763D0 (zh)
GR (1) GR3025668T3 (zh)
NZ (1) NZ259679A (zh)
RU (1) RU2128646C1 (zh)
WO (1) WO1994015912A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101001835B (zh) * 2004-09-01 2010-09-08 利奥制药有限公司 烯丙醇的差向异构化
CN101400649B (zh) * 2006-03-17 2012-07-04 利奥制药有限公司 药物中间体的异构化

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU710931B2 (en) * 1996-02-28 1999-09-30 Sumitomo Pharmaceuticals Company, Limited Crystalline vitamin D derivative
US8263580B2 (en) * 1998-09-11 2012-09-11 Stiefel Research Australia Pty Ltd Vitamin formulation
SI2915534T1 (sl) 1999-04-23 2018-10-30 Leo Pharma A/S Farmacevtski sestavek za dermalno uporabo za zdravljenje psoriaze, ki vsebuje vitamin D in kortikosteroid
US20090098065A1 (en) * 2000-01-11 2009-04-16 Avikam Harel Composition and methods for the treatment of skin disorders
AU2003291810A1 (en) * 2002-11-18 2004-06-15 Teva Pharmaceutical Industries Ltd. A crystallization method for purification of calcipotriene
MY139521A (en) * 2004-03-18 2009-10-30 Leo Pharma As Stereoselective synthesis of vitamin d analogues
FR2871696B1 (fr) * 2004-06-17 2006-11-10 Galderma Sa Composition topique pour le traitement du psoriasis
PL2526930T3 (pl) * 2005-06-01 2014-05-30 Glaxosmithkline Ip Dev Ltd Formulacja witaminowa
EP1987023B1 (en) * 2006-02-10 2010-11-24 Amgen, Inc Hydrate forms of amg706
WO2008027532A2 (en) * 2006-08-29 2008-03-06 Teva Pharmaceutical Industries Ltd. Pharmaceutical compositions including vitamin d and corticosteroid
US20100056644A1 (en) * 2006-11-29 2010-03-04 Nilendu Sen Pharmaceutical compositions containing anhydrous calcipotriene
ES2272198B1 (es) * 2006-12-28 2008-06-01 Laboratorios Viñas S.A. Procedimiento para la obtencion de hidrato de calcipotriol.
EP1970048A1 (en) * 2007-03-15 2008-09-17 Drug Delivery Solutions Limited Polyaphron topical composition with vitamin D
US10265265B2 (en) * 2007-03-15 2019-04-23 Drug Delivery Solutions Limited Topical composition
EP2008651A1 (en) 2007-06-26 2008-12-31 Drug Delivery Solutions Limited A bioerodible patch
CA2723540C (en) * 2008-05-08 2016-01-05 United Therapeutics Corporation Treprostinil monohydrate
WO2011002756A2 (en) * 2009-07-01 2011-01-06 Vitamin Derivatives, Inc. Vitamin d compounds and methods for preparing same
US9254296B2 (en) 2009-12-22 2016-02-09 Leo Pharma A/S Pharmaceutical composition comprising vitamin D analogue and cosolvent-surfactant mixture
CN102770125B (zh) * 2009-12-22 2015-02-11 利奥制药有限公司 钙泊三醇一水化合物纳米晶体
JP5873439B2 (ja) 2009-12-22 2016-03-01 レオ ファーマ アクティーゼルスカブ ビタミンｄ類似体および溶媒と界面活性剤の混合物を含む皮膚組成物
NZ601001A (en) * 2009-12-22 2014-07-25 Leo Pharma As Pharmaceutical composition comprising solvent mixture and a vitamin d derivative or analogue
NZ601002A (en) * 2009-12-22 2014-09-26 Leo Pharma As Pharmaceutical composition comprising vitamin d analogue and cosolvent-surfactant mixture
RS53809B1 (en) 2010-06-11 2015-06-30 Leo Pharma A/S PHARMACEUTICAL COMPOSITION SKIN SPRAY CONTAINING VITAMIN D ANALYSIS AND CORTICOSTEROID
ES2736256T3 (es) 2011-03-14 2019-12-27 Drug Delivery Solutions Ltd Composición oftálmica
RU2602171C2 (ru) 2011-03-24 2016-11-10 Лео Фарма А/С Композиция, содержащая липидные наночастицы и кортикостероид или производное витамина d
JP5652723B2 (ja) * 2012-08-17 2015-01-14 フォーモサ・ラボラトリーズ・インコーポレーテッド マキサカルシトールの新しい結晶形態
CN103724162A (zh) * 2014-01-07 2014-04-16 成都医路康医学技术服务有限公司 一种银屑病治疗药物卡泊三醇溶剂化物的制备方法
MA41818A (fr) 2015-03-27 2018-01-30 Leo Pharma As Timbre à micro-aiguilles pour administration d'un principe actif à la peau
EP3542788A1 (en) 2018-03-19 2019-09-25 MC2 Therapeutics Limited Topical composition comprising calcipotriol and betamethasone dipropionate

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2457282A1 (fr) * 1979-05-23 1980-12-19 Roussel Uclaf Nouveau derive du 1a,25 dihydroxy cholecalciferol, son procede de preparation et son application comme medicament
JPS59104358A (ja) 1982-12-03 1984-06-16 Teijin Ltd １α，２４−ジヒドロキシコレカルシフエロ−ルの一水塩及びその製造法
EP0227826B1 (en) * 1985-08-02 1989-10-25 Leo Pharmaceutical Products Ltd. A/S (Lovens Kemiske Fabrik Produktionsaktieselskab) Novel vitamin d analogues
GB9004544D0 (en) * 1990-03-01 1990-04-25 Leo Pharm Prod Ltd Novel treatment ii

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101001835B (zh) * 2004-09-01 2010-09-08 利奥制药有限公司 烯丙醇的差向异构化
CN101400649B (zh) * 2006-03-17 2012-07-04 利奥制药有限公司 药物中间体的异构化

Also Published As

Publication number Publication date
GR3025668T3 (en) 1998-03-31
NZ259679A (en) 1996-11-26
GB9300763D0 (en) 1993-03-03
JP3729847B2 (ja) 2005-12-21
CN1040746C (zh) 1998-11-18
USRE39706E1 (en) 2007-06-26
EP0679154A1 (en) 1995-11-02
JPH08505612A (ja) 1996-06-18
EP0679154B1 (en) 1997-10-29
ATE159717T1 (de) 1997-11-15
DK0679154T3 (da) 1998-03-30
AU663249B2 (en) 1995-09-28
FI108638B (fi) 2002-02-28
WO1994015912A1 (en) 1994-07-21
KR950704249A (ko) 1995-11-17
KR100309751B1 (ko) 2002-11-08
RU95116650A (ru) 1997-06-10
US5763426A (en) 1998-06-09
AU5857394A (en) 1994-08-15
DE69406529T2 (de) 1998-05-28
CA2151730A1 (en) 1994-07-21
RU2128646C1 (ru) 1999-04-10
FI952797A0 (fi) 1995-06-07
FI952797A (fi) 1995-06-07
DE69406529D1 (de) 1997-12-04
CA2151730C (en) 2005-01-04
ES2111287T3 (es) 1998-03-01

Similar Documents

Publication Publication Date Title
CN1040746C (zh) 维生素d类似物的新晶形
PT78146A (en) Process for the preparation of solid pharmaceutical compositions
FR2468577A1 (fr) Nouveaux 5z,8z,11z,14z,17z-eicosapentaenoates d'alkylphenyle, utiles notamment comme inhibiteurs de l'agglomeration des plaquettes sanguines et agents antisecretoires
KR870001071B1 (ko) 고 결정성 나트륨 세포페라존의 제조방법
EP0028336B1 (en) Derivative of creatinol-o-phosphate having therapeutical action, process for the preparation thereof and related pharmaceutical compositions
US20140113886A1 (en) Stabilized 1, 25-Dihydroxyvitamin D2 and Method of Making Same
AU712904B2 (en) Improved process for preparing potassium clavulanate
US20030186956A1 (en) Process for drying amoxicillin
JP2677906B2 (ja) パラ−アミノベンゼンスルファニルアミドの物理的に安定した結晶性α−変態の調製方法
KR860001495B1 (ko) 결정성 나트륨 세포페라존의 제조방법
EP0018811B1 (en) Antibiotic crystalline epimer, its preparation and pharmaceutical composition containing it
RU2074858C1 (ru) Кристаллический дигидрат (5r, 6s)-2-карбамоилоксиметил-6-[(1r)-гидроксиэтил]-2-пенем-3-карбоновой кислоты, способ его получения, фармацевтическая композиция
EP0006223A1 (en) Crystalline sodium and potassium indomethacin and their trihydrates, process for preparing and pharmaceutical compositions containing the same
CN1814612A (zh) 马来酸氨柔比星盐及其制备方法和用途
CH645901A5 (fr) Sel sesqui-sodique d'un diacide d'oxa-beta-lactame antibiotique.
JPH09291073A (ja) 結晶態のビタミンｄ誘導体
JPH0673085A (ja) デカプラニン塩溶液および結晶デカプラニン塩ならびにそれらの調製方法
CH333365A (fr) Procédé pour la préparation de tétracycline libre pratiquement pure
JPH053848B2 (zh)

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CX01 Expiry of patent term

Expiration termination date: 20140107

Granted publication date: 19981118

CX01 Expiry of patent term